Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Natalizumab Re-Initiation in MS
NCT00306592Phase 3Completed
- Sponsor
- Biogen
- Start
- Mar 2006
- Primary completion
- Dec 2007
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of natalizumab in multiple sclerosis (MS), sponsored by Biogen. Started Mar 2006; status: completed.
02
Drugs
natalizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00306592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00306592.